MX2017003063A - Prueba de diagnostico basada en fragmento de rgma. - Google Patents
Prueba de diagnostico basada en fragmento de rgma.Info
- Publication number
- MX2017003063A MX2017003063A MX2017003063A MX2017003063A MX2017003063A MX 2017003063 A MX2017003063 A MX 2017003063A MX 2017003063 A MX2017003063 A MX 2017003063A MX 2017003063 A MX2017003063 A MX 2017003063A MX 2017003063 A MX2017003063 A MX 2017003063A
- Authority
- MX
- Mexico
- Prior art keywords
- diagnostic assay
- based diagnostic
- fragment based
- rgma fragment
- rgma
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/285—Demyelinating diseases; Multipel sclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Ophthalmology & Optometry (AREA)
- Psychology (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- Obesity (AREA)
Abstract
Se proveen pruebas de diagnóstico y métodos para utilizar las pruebas de diagnóstico para detectar y cuantificar fragmentos de RGMa en una muestra. Los métodos se pueden utilizar en la detección de los fragmentos de RGMa para monitorear el tratamiento con fármaco y la efectividad del tratamiento con fármaco en enfermedades neurodegenerativas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462048745P | 2014-09-10 | 2014-09-10 | |
PCT/EP2015/070603 WO2016038084A1 (en) | 2014-09-10 | 2015-09-09 | Rgma fragment based diagnostic assay |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017003063A true MX2017003063A (es) | 2017-06-14 |
Family
ID=54064367
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017003063A MX2017003063A (es) | 2014-09-10 | 2015-09-09 | Prueba de diagnostico basada en fragmento de rgma. |
MX2021009528A MX2021009528A (es) | 2014-09-10 | 2017-03-08 | Prueba de diagnostico basada en fragmento de rgma. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021009528A MX2021009528A (es) | 2014-09-10 | 2017-03-08 | Prueba de diagnostico basada en fragmento de rgma. |
Country Status (10)
Country | Link |
---|---|
US (3) | US20160069907A1 (es) |
EP (1) | EP3191847A1 (es) |
JP (1) | JP6879905B2 (es) |
CN (2) | CN113267630A (es) |
AU (2) | AU2015314240A1 (es) |
BR (1) | BR112017004883A2 (es) |
CA (1) | CA2956814A1 (es) |
MX (2) | MX2017003063A (es) |
TW (2) | TW201617612A (es) |
WO (1) | WO2016038084A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007067416A2 (en) * | 2005-12-05 | 2007-06-14 | Affinium Pharmaceuticals, Inc. | Heterocyclylacrylamide compounds as fabi inhibitors and antibacterial agents |
CA2780069C (en) * | 2009-12-08 | 2018-07-17 | Abbott Gmbh & Co. Kg | Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration |
CA3112511A1 (en) | 2018-07-19 | 2020-01-23 | The University Of Tokyo | Therapeutic or prophylactic agent for htlv-1-associated myelopathy (ham), and method for treating ham |
WO2021145432A1 (ja) * | 2020-01-15 | 2021-07-22 | 国立大学法人大阪大学 | 糖尿病性自律神経障害の予防又は治療剤 |
CN112402554B (zh) * | 2020-10-26 | 2022-03-01 | 中国中医科学院广安门医院 | 一种治疗脑白质病的中药组合物及其应用 |
EP4374300A1 (en) * | 2021-07-23 | 2024-05-29 | Cedars-Sinai Medical Center | Methods and systems for early detection of ocular and/or neurological conditions |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1095278T3 (da) * | 1998-07-03 | 2006-04-18 | Innogenetics Nv | Differentialdiagnose af neurodegeneration |
ES2390425T3 (es) * | 2000-12-22 | 2012-11-12 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Uso de moléculas de orientación repulsivas (RGM) y sus moduladores |
US8962803B2 (en) | 2008-02-29 | 2015-02-24 | AbbVie Deutschland GmbH & Co. KG | Antibodies against the RGM A protein and uses thereof |
CA2780069C (en) | 2009-12-08 | 2018-07-17 | Abbott Gmbh & Co. Kg | Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration |
US9334323B2 (en) * | 2009-12-09 | 2016-05-10 | Mitsubishi Tanabe Pharma Corporation | Method of reducing recurrence of multiple sclerosis symptoms in a mammal by administering an anti-repulsive guidance molecule neutralizing antibody |
CN103298834A (zh) * | 2010-08-03 | 2013-09-11 | Abbvie公司 | 双重可变结构域免疫球蛋白及其用途 |
US9125894B2 (en) * | 2010-10-06 | 2015-09-08 | Massachusetts Eye & Ear Infirmary | Methods for promoting reinnervation of auditory hair cells |
CA2839777C (en) * | 2011-06-22 | 2021-10-19 | Universite Laval | Methods for the prognostic and/or diagnostic of neurodegenerative disease, methods to identify candidate compounds and compounds for treating neurodegenerative disease |
MY194587A (en) * | 2012-01-27 | 2022-12-05 | Abbvie Inc | Composition and method for the diagnosis and treatment of diseases associated with neurite degeneration |
-
2015
- 2015-09-09 CN CN202110521844.0A patent/CN113267630A/zh active Pending
- 2015-09-09 AU AU2015314240A patent/AU2015314240A1/en not_active Abandoned
- 2015-09-09 TW TW104129821A patent/TW201617612A/zh unknown
- 2015-09-09 CA CA2956814A patent/CA2956814A1/en not_active Abandoned
- 2015-09-09 EP EP15759819.4A patent/EP3191847A1/en not_active Withdrawn
- 2015-09-09 BR BR112017004883A patent/BR112017004883A2/pt not_active IP Right Cessation
- 2015-09-09 JP JP2017513509A patent/JP6879905B2/ja active Active
- 2015-09-09 CN CN201580048412.5A patent/CN107076757A/zh active Pending
- 2015-09-09 MX MX2017003063A patent/MX2017003063A/es unknown
- 2015-09-09 TW TW109124697A patent/TW202119030A/zh unknown
- 2015-09-09 WO PCT/EP2015/070603 patent/WO2016038084A1/en active Application Filing
- 2015-09-10 US US14/850,185 patent/US20160069907A1/en not_active Abandoned
-
2017
- 2017-03-08 MX MX2021009528A patent/MX2021009528A/es unknown
-
2019
- 2019-09-04 US US16/560,632 patent/US20200241012A1/en not_active Abandoned
-
2021
- 2021-03-02 US US17/190,135 patent/US20220018855A1/en not_active Abandoned
-
2022
- 2022-01-12 AU AU2022200160A patent/AU2022200160A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20220018855A1 (en) | 2022-01-20 |
JP2017526930A (ja) | 2017-09-14 |
US20200241012A1 (en) | 2020-07-30 |
AU2022200160A1 (en) | 2022-02-10 |
CN107076757A (zh) | 2017-08-18 |
TW201617612A (zh) | 2016-05-16 |
JP6879905B2 (ja) | 2021-06-02 |
EP3191847A1 (en) | 2017-07-19 |
CN113267630A (zh) | 2021-08-17 |
US20160069907A1 (en) | 2016-03-10 |
BR112017004883A2 (pt) | 2017-12-05 |
AU2015314240A1 (en) | 2017-02-09 |
MX2021009528A (es) | 2021-09-08 |
WO2016038084A1 (en) | 2016-03-17 |
CA2956814A1 (en) | 2016-03-17 |
TW202119030A (zh) | 2021-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021009528A (es) | Prueba de diagnostico basada en fragmento de rgma. | |
HK1257999A1 (zh) | 用於臨床應用的分析物收集、提取、濃縮和檢測的方法和裝置 | |
CL2017003069A1 (es) | Métodos para diagnosticar y tratar el cáncer. | |
GB2552267B (en) | Detection and treatment of disease exhibiting disease cell heterogeneity and systems and methods for communicating test results | |
PL3482209T3 (pl) | Oznaczenie do wykrywania alfa-synukleiny i sposób diagnozowania alfa-synukleinopatii | |
SG10201408391RA (en) | Means and methods for multimodality analysis and processing ofdrilling mud | |
EP3186397C0 (en) | USE OF BIOMARKERS OF CIRCULATING CELLS IN THE BLOOD FOR THE DETECTION AND DIAGNOSIS OF DISEASES, AND THEIR ISOLATION PROCESSES | |
PH12017501967A1 (en) | Maize plant dbn9936 and method for use in detecting nucleic acid sequence thereof | |
EP3209998A4 (en) | Method and system for detection of disease agents in blood | |
EP3171161A4 (en) | Biological substance quantitative determination method, image processing device, pathological diagnosis support system, and program | |
FR3029288B1 (fr) | Procede de detection et de caracterisation par ultrasons de defauts dans un materiau heterogene | |
IL265712B (en) | A method for identifying active forms of an analyte and determining the ability of substances to bind with active sites of an analyte | |
EP3200118A4 (en) | Sample traceability device and method for medical research and/or diagnosis | |
WO2015013508A3 (en) | Methods for diagnosing and treating immune disease | |
HK1214649A1 (zh) | 體外診斷分析方法和系統 | |
NZ716643A (en) | Methods for predicting the risk of having a cardiovascular event and for monitoring the treatment of a cardiovascular event | |
MX2022010954A (es) | Dispositivo para la deteccion de proteinas mal plegadas y metodos de uso del mismo. | |
BR112016028838A2 (pt) | anticorpos, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, métodos de detecção de lgr5 humano em uma amostra biológica, de detecção de um câncer, de identificação de um paciente com câncer, de seleção de um paciente com câncer para tratamento com um imunoconjugado e de tratamento de um paciente com câncer | |
WO2015042326A3 (en) | Methods for detection and treatment of neurodegenerative diseases | |
SG11201509866TA (en) | Protease-responsive peptide biosensors and methods for analyte detection | |
EP3207374A4 (en) | Method and system for determining the concentration of an analyte in a fluid sample | |
IN2014KN00742A (es) | ||
EP3206032A4 (en) | Method for detecting cardiac failure patient, method for discrimination of cardiac disease, test reagent for cardiac failure, test kit for cardiac failure, device for detecting cardiac failure, and program for detecting cardiac failure | |
GB2530521B (en) | Mass spectral analysis of patient samples for the detection of the human chorionic gonadotropin | |
PL3230910T3 (pl) | Sposób zarządzania protokołami używanymi przez urządzenia do analizy diagnostycznej i klinicznej oraz wynikami uzyskanymi przez te urządzenia |